Heron Therapeutics, Inc. (NASDAQ:HRTX) – Cantor Fitzgerald issued their FY2017 earnings per share estimates for Heron Therapeutics in a research report issued on Monday. Cantor Fitzgerald analyst L. Chen expects that the biotechnology company will post earnings per share of ($3.32) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.

Several other research analysts also recently commented on the company. Zacks Investment Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 7th. Aegis reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, March 21st. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Cowen and Company reaffirmed a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a report on Friday, May 26th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Heron Therapeutics in a report on Monday, April 10th. Two research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $34.50.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/28/heron-therapeutics-inc-expected-to-post-fy2017-earnings-of-3-32-per-share-hrtx.html.

Shares of Heron Therapeutics (NASDAQ HRTX) opened at 13.85 on Wednesday. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $24.00. The company has a 50-day moving average price of $14.32 and a 200-day moving average price of $14.12.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to analyst estimates of $1.96 million.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc raised its position in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,098 shares during the period. Venturi Wealth Management LLC acquired a new position in Heron Therapeutics during the first quarter valued at $161,000. Pacad Investment Ltd. acquired a new position in Heron Therapeutics during the fourth quarter valued at $155,000. Old West Investment Management LLC acquired a new position in Heron Therapeutics during the first quarter valued at $206,000. Finally, Highbridge Capital Management LLC raised its position in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 252 shares during the period.

In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of Heron Therapeutics stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $15.33, for a total transaction of $330,238.86. Following the transaction, the vice president now directly owns 5,250 shares of the company’s stock, valued at approximately $80,482.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.31% of the stock is currently owned by insiders.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.